A survey of US dermatologists highlights inconsistent screening practices for comorbidities in patients with lichen planus.

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” ...

Lipella Pharmaceuticals Inc. announced that its abstract on LP-10, a liposomal tacrolimus oral rinse for treating Oral Lichen Planus (OLP), will be presented by Dr. Alessandro Villa at the 2025 ...

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

The post Lipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen Planus appeared first on PRISM MarketView.